Oncopeptides AB (publ) (LON:0RN4)
London
· Delayed Price · Currency is GBP · Price in SEK 1.787
-0.081 (-4.34%)
At close: May 27, 2025
Oncopeptides AB Statistics
Total Valuation
Oncopeptides AB has a market cap or net worth of GBP 28.96 million. The enterprise value is 30.96 million.
| Market Cap | 28.96M |
| Enterprise Value | 30.96M |
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 211.26M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +116.81% |
| Shares Change (QoQ) | -2.20% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 182.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.43 |
| PB Ratio | -64.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.45 |
| EV / Sales | 10.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -1.53 |
Financial Position
The company has a current ratio of 3.22
| Current Ratio | 3.22 |
| Quick Ratio | 3.09 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.51 |
| Interest Coverage | -24.37 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -92.72% |
| Return on Invested Capital (ROIC) | -148.84% |
| Return on Capital Employed (ROCE) | -217.56% |
| Revenue Per Employee | 40,963 |
| Profits Per Employee | -285,372 |
| Employee Count | 80 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 0.42 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -35.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -35.09% |
| 50-Day Moving Average | 1.81 |
| 200-Day Moving Average | 1.80 |
| Relative Strength Index (RSI) | 37.64 |
| Average Volume (20 Days) | 3,968 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Oncopeptides AB had revenue of GBP 3.07 million and -21.40 million in losses. Loss per share was -0.11.
| Revenue | 3.07M |
| Gross Profit | 2.90M |
| Operating Income | -21.34M |
| Pretax Income | -21.37M |
| Net Income | -21.40M |
| EBITDA | -21.15M |
| EBIT | -21.34M |
| Loss Per Share | -0.11 |
Balance Sheet
The company has 8.27 million in cash and 10.26 million in debt, giving a net cash position of -1.99 million.
| Cash & Cash Equivalents | 8.27M |
| Total Debt | 10.26M |
| Net Cash | -1.99M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | -450,539 |
| Book Value Per Share | -0.00 |
| Working Capital | 7.90M |
Cash Flow
In the last 12 months, operating cash flow was -20.17 million and capital expenditures -27,527, giving a free cash flow of -20.19 million.
| Operating Cash Flow | -20.17M |
| Capital Expenditures | -27,527 |
| Free Cash Flow | -20.19M |
| FCF Per Share | n/a |
Margins
| Gross Margin | 94.25% |
| Operating Margin | -694.63% |
| Pretax Margin | -695.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Oncopeptides AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -116.81% |
| Shareholder Yield | n/a |
| Earnings Yield | -73.90% |
| FCF Yield | -69.72% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |